AmbioPharm

Photo
15.11.2024 • News • Bioprocessing

Ambiopharm Breaks Ground on $28 Million Expansion

Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.

Photo
04.10.2023 • News

AmbioPharm Appoints Brian Gregg as CEO

Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Photo
07.11.2022 • News

Ariceum and AmbioPharm in Peptide Partnership

Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers, and AmbioPharm, a globally oriented US CDMO specialized in peptides, have agreed a strategic partnership in peptide conjugates.

Top-Feature

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Photo
AmbioPharm, Inc.